DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 16350.0
(-1.57%)
KRW 16350.0
(-1.57%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 104.74 Billion KRW | 14.62% |
| 2022 | 91.38 Billion KRW | -24.01% |
| 2021 | 120.25 Billion KRW | 35.95% |
| 2020 | 88.45 Billion KRW | 46.72% |
| 2019 | 60.28 Billion KRW | 9.05% |
| 2018 | 55.28 Billion KRW | 459.88% |
| 2017 | 9.87 Billion KRW | 75.78% |
| 2016 | 5.61 Billion KRW | -33.5% |
| 2015 | 8.44 Billion KRW | 38.61% |
| 2014 | 6.09 Billion KRW | 68.74% |
| 2013 | 3.61 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 75.82 Billion KRW | -21.1% |
| 2024 Q1 | 96.1 Billion KRW | -8.25% |
| 2023 Q3 | 96.82 Billion KRW | 3.43% |
| 2023 Q4 | 104.74 Billion KRW | 8.18% |
| 2023 FY | 104.74 Billion KRW | 14.62% |
| 2023 Q1 | 90.86 Billion KRW | -0.56% |
| 2023 Q2 | 93.61 Billion KRW | 3.03% |
| 2022 Q1 | 102.76 Billion KRW | -14.54% |
| 2022 Q3 | 90.42 Billion KRW | 1.53% |
| 2022 Q2 | 89.06 Billion KRW | -13.33% |
| 2022 FY | 91.38 Billion KRW | -24.01% |
| 2022 Q4 | 91.38 Billion KRW | 1.05% |
| 2021 Q4 | 120.25 Billion KRW | 9.96% |
| 2021 Q1 | 90.06 Billion KRW | 36.52% |
| 2021 FY | 120.25 Billion KRW | 35.95% |
| 2021 Q2 | 106.7 Billion KRW | 18.48% |
| 2021 Q3 | 109.35 Billion KRW | 2.49% |
| 2020 Q4 | 65.96 Billion KRW | 7.72% |
| 2020 Q3 | 61.24 Billion KRW | -26.28% |
| 2020 FY | 88.45 Billion KRW | 46.72% |
| 2020 Q1 | 58.21 Billion KRW | -3.44% |
| 2020 Q2 | 83.07 Billion KRW | 42.69% |
| 2019 Q4 | 60.28 Billion KRW | -13.75% |
| 2019 Q1 | 56.61 Billion KRW | 2.4% |
| 2019 Q2 | 56.74 Billion KRW | 0.23% |
| 2019 Q3 | 69.89 Billion KRW | 23.18% |
| 2019 FY | 60.28 Billion KRW | 9.05% |
| 2018 Q2 | 13.56 Billion KRW | 55.25% |
| 2018 FY | 55.28 Billion KRW | 459.88% |
| 2018 Q4 | 55.28 Billion KRW | 297.36% |
| 2018 Q3 | 13.91 Billion KRW | 2.56% |
| 2018 Q1 | 8.73 Billion KRW | -11.51% |
| 2017 Q4 | 9.87 Billion KRW | -21.75% |
| 2017 FY | 9.87 Billion KRW | 75.78% |
| 2017 Q1 | 4.98 Billion KRW | -11.2% |
| 2017 Q2 | 5.51 Billion KRW | 10.6% |
| 2017 Q3 | 12.61 Billion KRW | 128.74% |
| 2016 Q2 | 5.01 Billion KRW | -30.68% |
| 2016 FY | 5.61 Billion KRW | -33.5% |
| 2016 Q1 | 7.23 Billion KRW | -14.32% |
| 2016 Q3 | 4.43 Billion KRW | -11.69% |
| 2016 Q4 | 5.61 Billion KRW | 26.77% |
| 2015 Q2 | 5.76 Billion KRW | 12.12% |
| 2015 FY | 8.44 Billion KRW | 38.61% |
| 2015 Q3 | 8.34 Billion KRW | 44.76% |
| 2015 Q1 | 5.14 Billion KRW | -15.62% |
| 2015 Q4 | 8.44 Billion KRW | 1.22% |
| 2014 FY | 6.09 Billion KRW | 68.74% |
| 2014 Q1 | 5.35 Billion KRW | 48.29% |
| 2014 Q3 | 5.52 Billion KRW | 47.31% |
| 2014 Q2 | 3.75 Billion KRW | -29.93% |
| 2014 Q4 | 6.09 Billion KRW | 10.23% |
| 2013 Q3 | 3.66 Billion KRW | 166.2% |
| 2013 FY | 3.61 Billion KRW | 0.0% |
| 2013 Q2 | 1.37 Billion KRW | 25.27% |
| 2013 Q4 | 3.61 Billion KRW | -1.57% |
| 2013 Q1 | 1.1 Billion KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | -341.455% |
| CMG Pharmaceutical Co., Ltd. | 19.74 Billion KRW | -430.546% |
| Celltrion Pharm, Inc. | 162.52 Billion KRW | 35.551% |
| Huons Global Co., Ltd. | 254.93 Billion KRW | 58.912% |
| Enzychem Lifesciences Corporation | 5.65 Billion KRW | -1751.641% |
| Humedix Co., Ltd. | 2.7 Billion KRW | -3777.019% |
| Boditech Med Inc. | 10.56 Billion KRW | -891.187% |
| EuBiologics Co., Ltd. | 14.77 Billion KRW | -608.768% |
| FutureChem Co.,Ltd | 3.68 Billion KRW | -2744.427% |
| Huons Co., Ltd. | 124.61 Billion KRW | 15.941% |
| BNC Korea Co., Ltd. | 737.2 Million KRW | -14108.671% |
| AptaBio Therapeutics Inc. | 13.93 Billion KRW | -651.735% |